title: Chronic inflammatory demyelinating polyradiculoneuropathy in a patient with systemic lupus erythematosus and good outcome with rituximab treatment.
abstract: A patient with chronic inflammatory demyelinating polyradiculoneuropathy and systemic lupus erythematosus arising after rubella vaccination was initially treated with plasmapheresis, corticosteroids and intravenous immunoglobulins, with partial response. After shift to rituximab, most clinical symptoms improved markedly, emphasizing the possible role of this monoclonal antibody in conventional therapy-resistant cases.
authors.affiliation: Department of Neurology, Hospital Español, Belgrano 2975, C1209AAB Buenos Aires, Argentina.
authors.forename: P G
authors.initials: PG
authors.lastname: Sanz
authors.forename: C V
authors.initials: CV
authors.lastname: García Méndez
authors.forename: A L
authors.initials: AL
authors.lastname: Cueto
authors.forename: V B
authors.initials: VB
authors.lastname: Silva
authors.forename: J C
authors.initials: JC
authors.lastname: Walther
authors.forename: R A
authors.initials: RA
authors.lastname: Diez
authors.forename: S
authors.initials: S
authors.lastname: Martins
authors.forename: R J
authors.initials: RJ
authors.lastname: Giannaula
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000188:drug therapy*; D020277:Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / Q000150:complications / Q000188:drug therapy*; D019233:Retreatment; D000069283:Rituximab; D016896:Treatment Outcome
chemical_list: D000305:Adrenal Cortex Hormones; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D016756:Immunoglobulins, Intravenous; D000069283:Rituximab